Klaus Stoeckemann

Klaus Stoeckemann is a co-founder and Managing Partner of Peppermint Venture Partners (PVP). PVP focuses on investments in medical device and digital-health start-up companies in Germany and Europe. As a former General Partner in the 3i Healthcare Venture Capital team, he is a highly experienced venture capitalist with more than 13 years of experience in the Venture Capital industry.  He was responsible for more than 12 investments and exits during his tenure at 3i.  His track record at 3i includes the IPO of companies like Epigenomics and Jerini as well as the trade sales of Evotec Neuroscience, Amaxa and Elbion. Klaus has been board member of Combinature, Epigenomics, Jerini, Amaxa, Immatics as well as IntelliDx and Zonare in the US. He is currently chairman of the boards of Humedics, Emperra E-Health Technologies as well as Caterna Vision and board member of Implandata and focuses on digital health and medical device investments across Europe.  He holds a PhD in Biology and Pharmacology from the University of Mainz as well as a MBA from WHU / Kellogg Northwestern University in the US.